This combination boosts the presence of CD4<sup>+</sup> and CD8<sup>+</sup> tumor-infiltrating lymphocytes, reprograms tumor-associated macrophages toward an M1-like phenotype, and improves tumor control and metastasis reduction. This evidence concerns the gene CD8A and neoplasm.